Articles related to DRUG DISCOVERIES & DEVELOPMENT

In a significant advancement for knee osteoarthritis treatment, LEVI-04 demonstrated pain reduction in more than 50% of treated patients, with effects lasting through 20 weeks of study.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

A phase 3 trial demonstrates that aficamten improves oxygen utilization during exercise for obstructive HCM patients, indicating its potential to enhance daily functionality and quality of life.

In a landmark effort, seven molecules targeting the genetic roots of familial Parkinson’s disease were identified, showcasing the power of AI and open science in advancing treatment options. This collaborative achievement offers new avenues for understanding and potentially treating this challenging neurological disorder.